Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.
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6 CFU (A. flavus ND83) for the lungs of each mouse. Intranasal infection with A. fumigatus ND208 yielded 1.6 ϫ 10 7 CFU for the lungs of each mouse.
The survival of the mice was monitored throughout the treatment. Mean survival data for all treatment groups are summarized in Table 1 . Representative survival curves from individual experiments are shown in Fig. 1 . Similar trends were observed with the intranasal and inhalation routes of infection and with different strains and species of Aspergillus. G-CSF monotherapy at 125 or 600 g/kg/day was not protective against Aspergillus infection since all mice died by day 10. However, POS monotherapy was protective, enhancing survival from 0 to 41.7% (inhaled A. fumigatus), 83.3% (inhaled A. flavus), or 30% (intranasal A. fumigatus). Similarly, POS increased the survival of mice treated with G-CSF from 0% without POS to 22.2 to 66.6% (125 g of G-CSF/kg/day) and to 19.4 to 66.7% (600 g of G-CSF/kg/day) with POS (Table 1) . Thus, in contrast to a previous study by Graybill et al. (9) , we observed a dose-dependent increase in survival irrespective of whether POS was used alone or with G-CSF (Table 1) .
A comparison of survival of Aspergillus-infected mice treated with POS alone with survival of those treated with POS and G-CSF suggested a trend towards a decrease in survival of as much as 10 to 15%. However, an equivalent increase in survival was observed in some cases for individual experiments (e.g., for groups to which POS was given at 5 mg/kg/day with or without G-CSF [data not shown]). Moreover, at higher doses of POS, an increase in G-CSF from 125 to 600 g/kg/day appeared to have either no effect or a modestly beneficial effect (Table 1) . Overall, the differences between groups treated with POS alone and those treated with POS in combination with G-CSF were modest (ϳ10%; P Ͼ 0.05). These findings are in contrast to an earlier report that suggested that POS monotherapy was more efficacious than the combination of POS and G-CSF, with a 20 to 50% difference in mortality between the monotherapy and combination therapy groups (9) .
To determine the effect of POS-G-CSF combination therapy on the fungal burden in the lungs, the surviving mice from the high-dose POS groups were sacrificed on day 10 postinfection. The results for individual and combined drug experiments are shown in Table 2 and Fig. 2 . It is interesting that in contrast to the results of the earlier study by Graybill et al. (9) , mice surviving intranasal infection with A. fumigatus ND208 following POS monotherapy or POS-G-CSF combination therapy completely cleared infection (Fig. 2d) . The mice infected via the inhalation route did not clear infection. A modest trend toward an increased mean number of CFU per lung was observed with POS-G-CSF combination therapy in mice infected with A. fumigatus when the data from three individual studies were combined (n ϭ 5 to 10) ( Fig. 2a and b) . The number of data collected varied per individual study (n ϭ 2 to 5), and in some cases there was either no change or a decrease in the mean lung burden (Table 2 ). However, it should be noted that the number of animals tested in these groups was very small; therefore, no clear conclusions can be drawn from the lung burden data.
Interestingly, A. flavus ND83 infection, which resulted in the lowest mortality (Ͼ70% survival) (Fig. 1c) , also resulted in the least difference in mean numbers of CFU per lung between treatment groups (P Ͼ 0.05) (Fig. 2c) , suggesting that G-CSF has no significant effect on the antifungal activity of POS under these conditions. While lower mortality appears to present a clearer picture of similarities between monotherapy and combination therapy, this possibility could not be further substantiated by using a lower infecting dose of A. fumigatus, due to practical constraints of the inhalation model. Furthermore, in our hands, intranasal administration of A. fumigatus also resulted in Ͼ70% mortality at a dose for which Ͼ70% survival was observed by Graybill et al. (9) , highlighting some limitations of in vivo analyses.
Several factors may contribute to the differences in the survival rates and pathogen burdens between the present study and the previous study by Graybill et al. (9) . The mouse strain, age, and weight and the route of infection have all been shown to affect pathogen clearance and survival in pulmonary disease models of cryptococcosis (16) and coccidioidomycosis (4) .
Both the mouse weight (18 versus 30 g) and the strain used (CF-1 versus CD-1 [ICR]; both with the H-2 q haplotype) differed between this and the previous study by Graybill et al. (9) . However, no difference in susceptibility to Aspergillus infection or response to G-CSF or triazoles has been documented for these strains. Differences due to the Aspergillus strain used can be ruled out, since we observed similar trends with one strain of A. flavus and two strains of A. fumigatus, including the same clinical isolate, ND208 (94-2766), used by Graybill et al. (9) .
To address the possibility that the route of infection may play a role in susceptibility and response to therapy, we repeated the study using an intranasal route of infection with A. fumigatus ND208. An interesting difference was found in the clearance of A. fumigatus ND208 infection after intranasal or inhalation administration ( Fig. 2d; Table 2 ). This finding may suggest possible differences in infectivity or mechanisms and efficiency of pathogen clearance following different routes of infection. It is conceivable that the infectivity and dissemination of Aspergillus may differ in the lungs depending on ND208 [d] ). Each graph represents a single study (with 10 to 12 mice). Treatment consisted of sterile water for injection as a control (E), 600 g of G-CSF/kg/day (؋), or POS monotherapy at 100 mg/kg/day (A. fumigatus) or 10 mg/kg/day (A. flavus) (F). Combination therapy consisted of treatment with POS at 100 mg/kg/day for A. fumigatus or 10 mg/kg/day for A. flavus ND83 and G-CSF at either 125 g/kg/day (s) or 600 g/kg/day (OE). P values for all combinations were Ͼ0.05 by Wilcoxon and log rank test analyses. a Values in parentheses are numbers of surviving mice. POS was given at 100 mg/kg/day to mice infected with A. fumigatus and at 10 mg/kg/day to mice infected with A. flavus, with or without G-CSF. IN, intranasal infection; NS, no survivors; ND, not determined.
b P ϭ 0.0495. Unless otherwise indicated, no significant difference was observed between the lung burdens of surviving mice in combination therapy and those in monotherapy groups on day 10 postinfection (P Ͼ 0.05).
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on July 8, 2017 by guest http://aac.asm.org/ whether the infective dose is administered in solution or by aerosol, and as a result, the host response may also be affected. Generally, aerosolized infections result in diffuse bronchopneumonia with even distribution and replication primarily in lung tissue, whereas intranasal administration often results in upper respiratory tract infection (2). Thus, diffuse Aspergillus infection resulting from aerosol administration may contribute to the increased mortality and lung burden observed in the present study. Triazoles, including POS, inhibit lanosterol 14␣-demethylase. The net result is a depletion of ergosterol and the accumulation of methylated precursors in the fungal membrane (25) . These changes in membrane composition may result in increased sensitivity to oxygen-dependent immune mechanisms such as neutrophil attack (5, 24) . For example, ex vivo studies have shown that POS had a synergistic effect on the fungicidal activity of neutrophils against Scedosporium species (6) similar to properties of another triazole, voriconazole, against A. fumigatus (26, 27) . Similarly, fluconazole in combination with granulocyte macrophage-CSF increased monocyte killing of Candida albicans (3) . Thus, the combination of POS and G-CSF offers the possibility of direct inhibition of fungal growth, triazole-induced susceptibility to neutrophil-mediated killing, and enhancement of innate immunity by G-CSF (11, 18, 19, 23) .
In vivo studies using G-CSF-triazole combination therapy have reported either a beneficial response (7, 8, 13, 28) or no significant difference (12, 13) in the survival of infected mice. For example, fluconazole-G-CSF combination therapy had no effect on survival (ϳ10% difference) (12) . In another study, the same combination prolonged the survival of neutropenic mice at a low infecting dose of Candida (7) . However, at high infecting doses, the differences in survival were marginal to none (10 to 30% decrease). In the present study, we report that combining G-CSF with POS does not substantially affect the antifungal efficacy of POS in a murine model of invasive aspergillosis, with differences observed in ranges similar to those of previous studies that reported a lack of effect of G-CSF on triazole efficacy.
